OTCMKTS:BICX Biocorrx (BICX) Stock Price, News & Analysis $0.34 -0.01 (-3.60%) As of 08/27/2025 01:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Biocorrx Stock (OTCMKTS:BICX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biocorrx alerts:Sign Up Key Stats Today's Range$0.34▼$0.3850-Day Range$0.34▼$0.4852-Week Range$0.20▼$1.45Volume2,501 shsAverage Volume301 shsMarket Capitalization$6.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California. Read More Biocorrx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreBICX MarketRank™: Biocorrx scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Biocorrx. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Biocorrx is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biocorrx is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biocorrx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.03% of the float of Biocorrx has been sold short.Short Interest Ratio / Days to CoverBiocorrx has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiocorrx does not currently pay a dividend.Dividend GrowthBiocorrx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.03% of the float of Biocorrx has been sold short.Short Interest Ratio / Days to CoverBiocorrx has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Biocorrx this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biocorrx insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of Biocorrx is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Biocorrx's insider trading history. Receive BICX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biocorrx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BICX Stock News HeadlinesDiamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)August 25, 2025 | globenewswire.comBioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) SalesAugust 14, 2025 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 29 at 2:00 AM | Porter & Company (Ad)BioCorRx Inc. (BICX) Latest Press Releases & Corporate News - Yahoo FinanceJune 1, 2025 | finance.yahoo.comBioCorRx Reports Business Update for the First Quarter of 2025May 20, 2025 | finance.yahoo.comBioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLCMarch 10, 2025 | finance.yahoo.comLa Rosa Holdings Corp. secures new financing, reshuffles leadershipOctober 6, 2024 | investing.comBioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2024August 16, 2024 | finanznachrichten.deSee More Headlines BICX Stock Analysis - Frequently Asked Questions How have BICX shares performed this year? Biocorrx's stock was trading at $0.38 at the beginning of 2025. Since then, BICX stock has decreased by 11.2% and is now trading at $0.3374. How were Biocorrx's earnings last quarter? Biocorrx Inc. (OTCMKTS:BICX) issued its earnings results on Thursday, August, 14th. The company reported ($0.07) earnings per share for the quarter. The firm earned $0.18 million during the quarter. How do I buy shares of Biocorrx? Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biocorrx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biocorrx investors own include PlayAGS (AGS), Ashford Hospitality Trust (AHT), Peabody Energy (BTU), Mondi (MNDI), Assertio (ASRT), Astronics (ATRO) and CONSOL Coal Resources (CCR). Company Calendar Last Earnings8/14/2025Today8/29/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolOTCMKTS:BICX CIK1443863 Webwww.biocorrx.com Phone(714) 462-4880FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.11 million Net MarginsN/A Pretax Margin-1,587.86% Return on EquityN/A Return on Assets-130.26% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.03 Sales & Book Value Annual Sales$10 thousand Price / Sales639.04 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-0.49Miscellaneous Outstanding Shares18,940,000Free Float14,884,000Market Cap$6.39 million OptionableNot Optionable Beta0.10 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:BICX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocorrx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biocorrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.